Caribou Biosciences Inc (CRBU) Stock Price, Quote & News

Company Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 982 6030

Website: cariboubio.com

Address:

2929 7th Street, Suite 105, Berkeley, United States

BlackForge Feb. 22 at 12:59 AM

$CRBU No Product Revenue & Ongoing Losses..

1 · Reply

IwannaRetire Feb. 21 at 6:43 PM

$CRBU Here’s what I am watching: CB11 data and potential designation for Best In Class. That BIC designation completely rerates the stock. Expecting 12mos CB11 data by ASCO in late May early June and then Pfizer makes a move. Caribou doesn’t have to accept Pfizer’s offer. Deal models could be similar in structure and potential as Gilead/Arcellx or J&J/Legend. Both of those had massive upfront payments. Caribou’s advantage is Allogenic vs both of those which were Autologous. It’s going to be an exciting 3-6mos !!! (I don’t think this goes as far as ASH in Dec. if the data stays amazing and Caribou does reject lowball offers then by ASH there will be 18mos of CB11 data and this could be a Seagen like bidding war.)

0 · Reply

Jidane Feb. 21 at 2:39 PM

$CRBU She or he didn’t listen to Citi conference call on February 19th. Just guessing and imagine only with her brain or ego without new input.

1 · Reply

GamblingFerret Feb. 21 at 9:29 AM

$CRBU Great call at Citi conference. Key insights: - FDA alignment & financing will be done in H1 - Phase 3 start in H2, data readout in 2028 - Regarding possible deals to finance phase 3, Rachel plans to bring CB10 to the US alone while seeking for partnerships outside US (after readout) - She did not mention CB11 in this context notably - CB10 Phase 3 will focus on 2L with double ineligibility for autologous / stem cell transplant. Only 25% of patients receive autologous therapy today, and the targeted patients stand for 60% of the rest. This means 45% of patient populations, exceeding today`s market share of all autologous therapies - Phase 3 success probability is very high, as CB10 will be compared to bispecifics / immunotherapy regimes without curative character and low PFS My summary: CB11 will be out licensed to Pfizer in H1 (Pfizer ROFN until June) to finance phase 3 study. Next step: FDA alignment announcement. This is going to skyrocket! https://kvgo.com/citi/caribou-biosciences-february-2026

1 · Reply

RocroBio Feb. 21 at 12:49 AM

$CRBU PFE loses ROFN in June…

0 · Reply

Reneejordan001 Feb. 20 at 8:19 PM

$CRBU A sale for 700M is possible here 🙏🤞

1 · Reply

Megabyte48 Feb. 20 at 2:03 PM

$CRBU impressed, finally broke the ceiling

2 · Reply

vu_jade Feb. 20 at 1:42 AM

$CRBU A few months ago this spike to $3.50 gave it all back .. could easily test that level again

0 · Reply

OverTheShoulderBagHolder Feb. 19 at 9:00 PM

$CRBU nice article in Forbes yesterday about J. Doudna and the future of gene editing. https://www.forbes.com/sites/amyfeldman/2026/02/17/gene-editing-has-struggled-to-go-commercial-this-nobel-laureate-has-a-1-billion-plan-to-fix-that/

0 · Reply

Sumner36 Feb. 19 at 8:55 PM

$CRBU I’m assuming someone liked what they heard at the fireside chat

1 · Reply

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 12, 2026, 4:05 PM EST - 9 days ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST - 17 days ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Dec 1, 2025, 4:05 PM EST - 2 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Nov 12, 2025, 4:05 PM EST - 3 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 11:48 AM EST - 3 months ago

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Nov 3, 2025, 7:00 AM EST - 3 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 3 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 2, 2025, 4:00 PM EST - 3 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Aug 25, 2025, 4:05 PM EDT - 6 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

May 28, 2025, 4:00 PM EDT - 9 months ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 10 months ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:00 PM EDT - 10 months ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Apr 24, 2025, 4:15 PM EDT - 10 months ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 10, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect

Apr 8, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out

Apr 6, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 11 months ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 11 months ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Mar 27, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Mar 25, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Mar 20, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Mar 16, 2025, 10:00 AM EDT - 1 year ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Mar 11, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 5:45 AM EST - 1 year ago

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Feb 23, 2025, 9:27 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 20, 2025, 1:28 PM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

Feb 19, 2025, 10:22 AM EST - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 15, 2025, 3:04 PM EST - 1 year ago

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Jan 29, 2025, 10:51 AM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

BlackForge Feb. 22 at 12:59 AM

$CRBU No Product Revenue & Ongoing Losses..

1 · Reply

IwannaRetire Feb. 21 at 6:43 PM

0 · Reply

Jidane Feb. 21 at 2:39 PM

$CRBU She or he didn’t listen to Citi conference call on February 19th. Just guessing and imagine only with her brain or ego without new input.

1 · Reply

GamblingFerret Feb. 21 at 9:29 AM

1 · Reply

RocroBio Feb. 21 at 12:49 AM

$CRBU PFE loses ROFN in June…

0 · Reply

Reneejordan001 Feb. 20 at 8:19 PM

$CRBU A sale for 700M is possible here 🙏🤞

1 · Reply

Megabyte48 Feb. 20 at 2:03 PM

$CRBU impressed, finally broke the ceiling

2 · Reply

vu_jade Feb. 20 at 1:42 AM

$CRBU A few months ago this spike to $3.50 gave it all back .. could easily test that level again

0 · Reply

OverTheShoulderBagHolder Feb. 19 at 9:00 PM

0 · Reply

Sumner36 Feb. 19 at 8:55 PM

$CRBU I’m assuming someone liked what they heard at the fireside chat

1 · Reply

FkGlobalists Feb. 19 at 7:35 PM

$CRBU

0 · Reply

YakoCapital Feb. 19 at 5:12 PM

$CRBU Let's go $3

0 · Reply

Goodstockday Feb. 19 at 3:40 PM

$CRBU No link for conference. Anyone have one?

1 · Reply

3DBuilds Feb. 19 at 1:58 PM

$CRBU $EDIT $JNJ $NTLA $PRME

0 · Reply

3DBuilds Feb. 19 at 2:38 AM

$CRBU $NTLA $PRME $EDIT $BMY Jennifer and Racheal 💯 Caribou is doing animals plants humans 🌎 💰 🙌

0 · Reply

vu_jade Feb. 18 at 9:14 PM

$CRBU $2.5 & $4 plus on tap

0 · Reply

prodigy81 Feb. 17 at 7:02 PM

$CRBU I heard about this company right now. Interesting company.

0 · Reply

vu_jade Feb. 17 at 6:18 PM

$CRBU trading around cash levels No volume

0 · Reply

vu_jade Feb. 17 at 3:25 PM

$CRBU buying the wedge

0 · Reply

3DBuilds Feb. 17 at 12:05 PM

$NTLA $CRBU $EDIT $PRME $JNJ Jennifer 💯 💰 🌎

0 · Reply

Sumner36 Feb. 14 at 4:17 PM

$CRBU https://www.stocktitan.net/news/CRBU/caribou-biosciences-to-participate-in-upcoming-investor-mzu0h6hpcbrv.html

0 · Reply

vu_jade Feb. 13 at 5:25 PM

$CRBU little news should take this to $2.5

0 · Reply

Market Cap	168.24M
Revenue (ttm)	9.99M
Net Income (ttm)	-149.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,492.59%
Debt to Equity Ratio	0.00

Volume	1,762,700
Avg Vol	1,104,274
Day's Range	N/A - N/A
Shares Out	93.47M
Stochastic %K	87%
Beta	2.61
Analysts	Strong Sell
Price Target	$10.88